Repare Therapeutics Shares Initial Data From Phase 1 MINOTAUR Trial Evaluating Lunresertib In Combination With FOLFIRI At ESMO GI Cancers Congress 2024
Portfolio Pulse from Benzinga Newsdesk
Repare Therapeutics (NASDAQ:RPTX) shared positive initial data from its Phase 1 MINOTAUR trial at the ESMO GI Cancers Congress 2024. The trial evaluates lunresertib in combination with FOLFIRI in patients with advanced solid tumors, showing an overall response of 18.2% and prolonged clinical benefit in CRC patients.
June 26, 2024 | 2:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Repare Therapeutics reported positive initial data from its Phase 1 MINOTAUR trial, showing promising results for lunresertib in combination with FOLFIRI in advanced solid tumors. This could boost investor confidence and positively impact the stock price in the short term.
The positive initial data from the Phase 1 MINOTAUR trial indicates potential efficacy of lunresertib in combination with FOLFIRI, which is likely to boost investor confidence. The prolonged clinical benefit in CRC patients and the establishment of a preliminary RP2D further support the potential success of the treatment, making the news highly relevant and important for RPTX investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100